243 related articles for article (PubMed ID: 15123247)
1. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
2. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
3. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided discovery of cyclin-dependent kinase inhibitors.
Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
7. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
[TBL] [Abstract][Full Text] [Related]
8. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
Sims PA; Wong CF; McCammon JA
J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
[TBL] [Abstract][Full Text] [Related]
10. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
[TBL] [Abstract][Full Text] [Related]
11. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
[TBL] [Abstract][Full Text] [Related]
12. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
Schulze-Gahmen U; De Bondt HL; Kim SH
J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.
García MD; Wilson AJ; Emmerson DP; Jenkins PR; Mahale S; Chaudhuri B
Org Biomol Chem; 2006 Dec; 4(24):4478-84. PubMed ID: 17268643
[TBL] [Abstract][Full Text] [Related]
14. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
15. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
[TBL] [Abstract][Full Text] [Related]
16. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.
VanderWel SN; Harvey PJ; McNamara DJ; Repine JT; Keller PR; Quin J; Booth RJ; Elliott WL; Dobrusin EM; Fry DW; Toogood PL
J Med Chem; 2005 Apr; 48(7):2371-87. PubMed ID: 15801830
[TBL] [Abstract][Full Text] [Related]
17. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
18. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
Aubry C; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Chem Commun (Camb); 2004 Aug; (15):1696-7. PubMed ID: 15278142
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
20. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
Honma T; Hayashi K; Aoyama T; Hashimoto N; Machida T; Fukasawa K; Iwama T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Iwasawa Y; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4615-27. PubMed ID: 11741479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
